LY2835219 supplier|cas 1231929-97-7 |DC Chemicals|Supplier|Price|Buy  

DC Chemicals Supply: LY2835219 supplier,cas 1231929-97-7, Cat No. DC5062, In stock

Contact: website: www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-61454686;Fax:+86-21-61642823；

Product name: LY2835219, Synonym:　LY2835219; LY-2835219; LY 2835219, Cat No. DC5062, Cas: 1231929-97-7, Chemical Name:N/A, Molecular Formula: C27H32F2N8, MW: 506.59339

LY2835219,cas 1231929-97-7, Purity: >98%. Best Price and quality in the market,DC Chemicals,Primary Manufacturer, confirmed by HNMR and HPLC. LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. CDK4/6 dual inhibitor LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.

LY2835219 is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. CDK4/6 dual inhibitor LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.